Coinheritance of BRCA1 and BRCA2 mutations with Fanconi anemia and Bloom syndrome mutations in Ashkenazi Jewish population: Possible role in risk modification for cancer development

American Journal of Hematology

Volumn 78, Issue 3, 2005, Pages 203-206

  Koren Michowitz, M ^a,b   Friedman, E ^a,b   Gershoni Baruch, R ^c   Brok Simoni, F ^a,b   Patael, Y ^a,b   Rechavi, G ^a,b   Amariglio, N ^a,b  

^a SHEBA MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c RAMBAM MEDICAL CENTER   (Israel)

Author keywords

Bloom syndrome; BRCA1; BRCA2; Fanconi anemia

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN;

ADULT; ARTICLE; BLOOM SYNDROME; BREAST CANCER; CANCER RISK; CANCER SUSCEPTIBILITY; CARCINOGENESIS; CONTROLLED STUDY; DNA REPAIR; FANCONI ANEMIA; FEMALE; GENE MUTATION; GENETIC SUSCEPTIBILITY; HETEROZYGOTE; HUMAN; INHERITANCE; JEW; MAJOR CLINICAL STUDY; ONSET AGE; OVARY CANCER; PRIORITY JOURNAL;

BLOOM SYNDROME; BREAST NEOPLASMS; FANCONI ANEMIA; FEMALE; GENE FREQUENCY; GENES, BRCA1; GENES, BRCA2; GENETIC PREDISPOSITION TO DISEASE; GENETIC SCREENING; GERM-LINE MUTATION; HUMANS; ISRAEL; JEWS; MIDDLE AGED; NEOPLASMS; OVARIAN NEOPLASMS; PREVALENCE; RISK;

EID: 14644389348     PISSN: 03618609     EISSN: None     Source Type: Journal    
DOI: 10.1002/ajh.20310     Document Type: Article

References (28)

1. Roa BB, Boyd AA, Volcik K, et al. Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2. Nat Genet 1996;14:185-187.
2. Struewing JP, Hartge P, Wacholder S, et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 1997;336:1401-1407.
3. King MC, Marks JH, Mandell JB, New York Breast Cancer Study Group. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 2003;302:643-646.
4. Rebbeck TR. Inherited predisposition and breast cancer: modifiers of BRCA1/2-associated breast cancer risk. Environ Mol Mutagen 2002;39:228-234.
5. Thompson D, Easton D, Breast Cancer Linkage Consortium. Variation in cancer risks, by mutation position, in BRCA2 mutation carriers. Am J Hum Genet 2001;68(2):410-419.
6. Amiramani E, Neuhausen SL, Tran T, Rebbeck TR, Weber BL. Polymorphisms in XRCC1 and XPD as breast cancer risk modifiers in BRCA1 mutation carriers. Am J Hum Genet 2001;69(Suppl 4):206.
7. Park JJ, Irvine RA, Buchanan G, et al. Breast cancer susceptibility gene 1 (BRCA1) is a coactivator of the androgen receptor. Cancer Res 2000;60(21):5946-5949.
8. Bochar DA, Wang L, Beniya H, et al. BRCA1 is associated with a human SWI/SNF-related complex: linking chromatin remodeling to breast cancer. Cell 2000;102(2):257-265.
9. Rebbeck TR, Kantoff PW, Krithivas K, et al. Modification of BRCA1-associated breast cancer risk by the polymorphic androgen-receptor CAG repeat. Am J Hum Genet 1999;64(5):1371-1377.
10. Hewlett NG, Taniguchi T, Olson S, et al. Biallelic inactivation of BRCA2 in Fanconi anemia. Science 2002;297:606-609.
11. Venkitaraman AR. Connecting Fanconi's anaemia to breast cancer predisposition. Lancet 2002;360(9343):1344-1345.
12. D'Andrea AD, Grompe M. Molecular biology of Fanconi anemia: implications for diagnosis and therapy. Blood 1997;90(5):1725-1736.
13. Joenje H, Oostra AB, Wijker M, et al. Evidence for at least eight Fanconi anemia genes. Am J Hum Genet 1997;61:940-944.
14. Nicotera TM. Molecular and biochemical aspects of Bloom's syndrome. Cancer Genet Cytogenet 1991;53:1-13.
15. German J. Bloom's syndrome. XX. The first 100 cancers. Cancer Genet Cytogenet 1997;93:100-106.
16. German J. Bloom's syndrome: a Mendelian prototype of somatic mutational disease. Medicine 1993;72:393-406.
17. Gruber SB, Ellis NA, Rennert G, et al. BLM heterozygosity and the risk of colorectal cancer. Science 2002;297:2013.
18. Oddoux C, Struewing JP, Clyton CM, et al. The carrier frequency of the BRCA2 6174delT mutation among Ashkenazi Jewish individuals is approximately 1%. Nat Genet 1996;14:188-190.
19. Whitney MA, Saito H, Jakobs PM, et al. A common mutation in the FACC gene causes Fanconi anemia in Ashkenazi Jews. Nature Genet 1993;4:202-205.
20. Verlander PC, Kaporis A, Liu Q, et al. Carrier frequency of the IVS4+ A to T mutation of the Fanconi anemia gene FAC in the Ashkenazi Jewish population. Blood 1995;86:4034-4038.
21. Peleg L, Pesso R, Goldman B. et al. Bloom syndrome and Fanconi's anemia: rate and ethnic origin of mutation carriers in Israel. Isr Med Assoc J 2002;4:95-97.
22. Ausubel FJ, Brent R, Kingston RE, et al. Current protocols in molecular biology. New York: John Wiley & Sons; 1996.
23. Straufhen JE, Johnson J, McLaren D, et al. A rapid method for detecting the predominant Ashkenazi Jewish mutation in the Bloom's syndrome gene. Hum Mutat 1998;11(2):175-178.
24. Thorlacius S, Struewing JP, Hartge P, et al. Population-based study of risk of breast cancer in carriers of BRCA2 mutation. Lancet 1998;352(9137):1337- 1339.
25. Kruyt FAE, Dijkmans LM, Arwert F, Joenje H. Involvement of the Fanconi anemia protein FAC in a pathway that signals to the cyclin B/cdc2 kinase. Cancer Res 1997;57:2244-2251.
26. D'Andrea AD. The Fanconi road to cancer. Genes Dev 2003;15;17(16):1933- 1936.
27. van der Heijden MS, Yeo CJ, Hruban RH, Kern SE. Fanconi anemia gene mutations in young-onset pancreatic cancer. Cancer Res 2003;63(10):2585-2588.
28. Taniguchi T, Tischkowitz M, Ameziane N, et al. Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors. Nat Med 2003;9(5):568-574.